peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Coffee and notepad

Press releases

2024

2 Feb 2024, 07:00 | Regulatory

· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD
6 Jan 2024, 14:00 | Regulatory

· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SR…

2023

14 Dec 2023, 20:00 | Regulatory
Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care
13 Dec 2023, 07:00 | Regulatory
26 Oct 2023, 07:00 | Regulatory
•    Encouraging high-level results for first-in-human trial of HNSA-5487
•    Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences
•    Dr. Hitto Kaufmann appointed new CSO
Load more
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.